122 related articles for article (PubMed ID: 29512738)
1. Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells.
Lacal PM; Atzori MG; Ruffini F; Tentori L; Graziani G
Oncol Rep; 2018 May; 39(5):2261-2269. PubMed ID: 29512738
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
[TBL] [Abstract][Full Text] [Related]
3. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.
Atzori MG; Tentori L; Ruffini F; Ceci C; Bonanno E; Scimeca M; Lacal PM; Graziani G
J Pharmacol Exp Ther; 2018 Jan; 364(1):77-86. PubMed ID: 29025978
[TBL] [Abstract][Full Text] [Related]
4. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
5. The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation.
Faraoni I; Aloisio F; De Gabrieli A; Consalvo MI; Lavorgna S; Voso MT; Lo-Coco F; Graziani G
Cancer Lett; 2018 Jun; 423():127-138. PubMed ID: 29526802
[TBL] [Abstract][Full Text] [Related]
6. Poly-(ADP-ribose) polymerases inhibition by olaparib attenuates activities of the NLRP3 inflammasome and of NF-κB in THP-1 monocytes.
Mustafa K; Han Y; He D; Wang Y; Niu N; Jose PA; Jiang Y; Kopp JB; Lee H; Qu P
PLoS One; 2024; 19(2):e0295837. PubMed ID: 38335214
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
8. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
[TBL] [Abstract][Full Text] [Related]
9. NFAT1 mediates placental growth factor-induced myelomonocytic cell recruitment via the induction of TNF-alpha.
Ding Y; Huang Y; Song N; Gao X; Yuan S; Wang X; Cai H; Fu Y; Luo Y
J Immunol; 2010 Mar; 184(5):2593-601. PubMed ID: 20097868
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
11. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
[TBL] [Abstract][Full Text] [Related]
12. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
[TBL] [Abstract][Full Text] [Related]
13. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
Anticancer Res; 2014 Oct; 34(10):5487-94. PubMed ID: 25275045
[TBL] [Abstract][Full Text] [Related]
16. The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor.
Atzori MG; Ceci C; Ruffini F; Scimeca M; Cicconi R; Mattei M; Lacal PM; Graziani G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428669
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
18. [Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
Lai FF; Li J; Ji M; Zhou Q; Wang LY; Chen XG
Yao Xue Xue Bao; 2016 Jun; 51(6):907-12. PubMed ID: 29879343
[TBL] [Abstract][Full Text] [Related]
19. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.
Liu W; Ren X; Wang Q; Zhang Y; Du J
Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):159-167. PubMed ID: 32865668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
